Validation of the Two-minute Walk Test and the Ten-meter Walk Test in Individuals With Cancer

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to assess the feasibility and the validity of the 2-minute walk test (2MWT) and the 10-meter walk test (10MeWT) compared to the 6-minute walk test (6MWT) for subjects with onco-hematological disease.

Detailed Description
-----------------
Cancer and its treatments have an impact on the body as a whole. The analysis of the subject's physical capacity is essential to know the basic level of the subject pre-treatment, to evaluate progress following rehabilitation, to set goals to prevent decline in physical capacity or to evaluate changes in physical capacity at different stages of survival. The 6-minute walk test (6MWT) is frequently used in the clinic to assess the physical capacity of the subject in oncology. A variant of the 6MWT exists and has been little studied in an oncological context: the 2-minute walk test (2MWT). The 2MWT is performed in the same way as the 6MWT: the same instructions and the same test procedure. It offers the advantage of being less tiring for the test subjects and saves clinicians time. The 2MWT has been validated in the past for people with COPD or after cardiac surgery. To our knowledge, it has not been validated for cancer patients. The 10-meter walk test (10MeWT) is frequently used in practice to assess patients' functional capacity. It would be another way to assess the walking ability with a short test. However, the relationship between the 2MWT, 6MWT and 10MeWT in an oncological context remain unclear.

Official Title
-----------------
Comparison of the 2MWT, the 10MeWT and the 6MWT in Individuals With Cancer, a Validation Observational Study.

Conditions
-----------------
Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: 6-minute walking test
* Diagnostic Test: 2-minute walking test
* Diagnostic Test: 10-meter walk test
* Diagnostic Test: One leg stance test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have an onco-hematologic disease Have medical authorization from the patient's oncologist authorizing gait tests Participate in the HUG rehabilitation program Be able to give consent by signature To be of legal age Do not present pain when walking more than 2/10 Be able to walk with or without technical aids for a period of 6 minutes (as per patient's statement) Exclusion Criteria: Suffer from heart problems Bone metastases at risk of fracture Osteoporosis at high risk of fracture Unbalanced Hypertension (hypertension) Not being able to carry out the walk tests in their entirety Not being able to perform the gait tests for reasons related to the side effects of the treatments (anemia, undernutrition, vomiting, severe fatigue, risk of thrombocytopenia, pain). Not being able to carry out the walking test because of a lack of understanding of the instructions or because of psychological problems.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cancer<br>Individuals with an oncology disease will be included in the study. | Diagnostic Test: 6-minute walking test<br>* The subject walks as far as possible for 6 minutes along a 30m long corridor.<br>Diagnostic Test: 2-minute walking test<br>* The subject walks as far as possible for 2 minutes along a 30m long corridor.<br>Diagnostic Test: 10-meter walk test<br>* The natural and fast walking speeds of the subject are measured over 10m. This speed is measured by the examiner as well as by the subject (self-tested version).<br>Diagnostic Test: One leg stance test<br>* The time held in unipodal equilibrium is measured by the examiner.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary endpoint: feasibility of the 2MWT and the 10MeWT | The feasibility of the different tests will be assessed in an oncological setting. | through study completion, an average of 1 year | 
| Primary endpoint: criterion validity with the 6MWT | Criterion validity will be assessed by calculating the strength of the correlation between the 2MWT/10MeWT and the 6MWT. | through study completion, an average of 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Secondary endpoint: convergent construct validity | Convergent construct validity will be evaluated by calculating the strength of the correlation between the 2MWT and the 10m walk test at comfortable/fast speed | through study completion, an average of 1 year | 
| Secondary endpoint: criterion validity between 10m walk test and 10m walk test self-tested | Criterion validity will be assessed by calculating the strength of the correlation between the 10m walk test self-tested and the 10m walk test timed by the examiner. | through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
6-minute walking test, 2-minute walking test, 10-meter walk test